Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT04879446 |
| Other study ID # |
19.U.019 |
| Secondary ID |
|
| Status |
Completed |
| Phase |
N/A
|
| First received |
|
| Last updated |
|
| Start date |
April 10, 2020 |
| Est. completion date |
March 15, 2021 |
Study information
| Verified date |
May 2021 |
| Source |
Mustafa Kemal University |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Interventional
|
Clinical Trial Summary
In this study, concentrated growth factor obtained by centrifuging the patient's own blood
and advanced platelet-rich fibrin liquids were applied to the implant cavity and surface.
Thus, it was aimed to ensure that the osseointegration process would start earlier by
ensuring a faster arrival of growth factor and healing mediators in the region, and thus, the
time waited for the osseointegration process and the loading of the superstructure would be
shortened.
In this split-mouth study, a total of 32 patients including two separate study groups in
different patients and a control group were included. While the CGF liquid was applied to the
implant cavities and surfaces prepared in the study group of 16 patients, A-PRF liquid was
applied to the study group of the other 16 patients. Conventional implant application was
performed in the control groups of both groups. The torque values during the implantation
were also recorded, and Resonance Frequency measurements were performed immediately after
implantation with the Penguin RFA device and at postoperative weeks 2, 4, 6 and 12.
Description:
This study was conducted in accordance with the Helsinki declaration on 32 patients who
applied to Hatay Mustafa Kemal University Faculty of Dentistry Department of Oral and
Maxillofacial Surgery to have dental implants in order to fix their missing teeth. 2 implants
with appropriate sizes and diameters were applied to each patient according to the condition
of the recipient bone in order to ensure standardization. It was aimed to ensure that the
primary stabilization of the implant would not be affected locally by applying implants to
the sites with similar bone density. The implants were placed symmetrically to the right and
left of the midline by the same physician provided that they were in the same jaw.
Some conditions were required for the inclusion of patients in the study, which were:
- Having no systemic disorder,
- Not being pregnant or breastfeeding,
- Having no smoking habit,
- Lack of continuous drug use due to chronic disease,
- No infection in the implant site and adjacent teeth,
- No previous implant or any augmentation procedure in the implant site,
- Adequate bone height and thickness of the implant site,
- The patient's acceptance and signing the informed consent form specific to study
describing the aim, duration, advantages and possible complications of the study.
Among the inclusion criteria in the study, no distinction was made between men and women, and
the patients without these criteria were not included in the study.
This study evaluating the effects of advanced platelet-rich fibrin and concentrated growth
factor liquids on dental implant osseointegration was planned as a randomized, clinical
controlled and prospective study. A total of 32 patients included in this study were divided
into two groups of 16. It was planned to apply 2 implants to each patient and to evaluate
each patient as one side as the control and the other as the study group. In other words,
while there was a study group and a control group in the CGF group, there was also a study
group and a control group in the A-PRF group. In the first group, it was planned to wash the
surface of one of the implants to be applied and the inside of the socket where the implant
would be placed with the CGF liquid obtained by centrifuging the patient's own blood, and to
apply a standard implant procedure without any application to the socket and surface of the
other implant to be applied.
In the second group, the surface of the implant in the study group the inside of the socket
where the implant would be placed were washed with the A-PRF liquid obtained by centrifuging
the patient's own blood, and standard conventional implant procedure was applied without any
application to the implant socket and surface in the control group.
Obtaining the CGF Liquid:
Sterile, single use, anticoagulant-free tube (Vacutest®, Arzergrande-Italy), syringe sets for
taking blood, skin disinfectant, centrifuge device produced suitable for tubes (MEDIFUGE,
Italy), and a special sterile container for obtaining the serum part of the concentrated
growth factor were used for the preparation of the concentrated growth factor. 2 x 9 cc.
venous blood samples taken intravenously from the patients were placed in the centrifuge
machine in tubes without shaking.
By operating the centrifuge in CGF mode, the device accelerated with an acceleration of 30
seconds and was centrifuged for 2 minutes at 2700 rpm, 4 minutes at 2400 rpm, 4 minutes at
2700 rpm and 3 minutes at 3000 rpm, and then the device stopped with an acceleration of 36
seconds. The process and periods of change of all this turnover rate are automatically
adjusted by the device. After the centrifugation process, 3 layers occur in the tube. These
layers were platelet-poor plasma layer at the top, red blood cell layer at the bottom, and
concentrated growth factor layer in the middle, respectively. The concentrated growth factor
formed was separated from the red blood cell layer in the lower layer with the help of
scissors by holding it with the help of a hemostat. However, during the separation process,
the part containing CD34+ stem cells was kept below the concentrated growth factor. Then, the
CGF was placed in a special sterile perforated container, pressed in the container and turned
into a membrane. Thus, the serum part of CGF was obtained by means of the holes in the
container.
Obtaining the A-PRF Liquid:
Sterile, single use, anticoagulant-free A-PRF tube, centrifuge device Duo centrifuge (Process
for PRF, France) produced suitable for these tubes, and a special sterile container for
obtaining the serum part of the A-PRF were used for the preparation of the A-PRF.
2x10 cc. venous blood samples taken intravenously from the patients were placed in the
centrifuge device without shaking, and centrifugation was set at 1300 rpm for 14 minutes.
While the A-PRF clot formed after the centrifugation was separated from the lower red blood
cell layer with the help of a hemostat, attention was paid not to remove this layer
completely. Then, this fibrin clot was pressed in a special sterile perforated contained and
A-PRF liquid was obtained.
Surgical Procedure:
All surgical procedures were performed as a double-blind study by the same surgical team.
After providing local anesthesia in the region, a crestal incision was made in the area to be
implanted using a scalpel number 15, and then, full-thickness mucoperiosteal flap was
removed. After the study and control groups were randomly determined, the implant socket was
prepared in appropriate size and diameter according to the surgical kit of the implant system
(Nucleoss T6, Turkey). In the study group of the concentrated growth factor, the surface of
the implant and the socket where the implant would be placed were washed with the CGF liquid
and placed in the implant socket without deterioration of sterility (Figure 2). The implant
in the control group was placed in its socket with the standard implant procedure without any
procedure. Similarly, the implants were placed in their sockets as stated above in the study
and control groups of the advanced platelet-rich fibrin. After all the implants in the study
and control groups were placed in the socket, the adjustable ratchet torque on the carrying
piece on it placed in 1 mm subcrestal position with a wrench in the buccal and
lingual/palatinal area. Thus, torque values were also recorded. The ratchet wrench measuring
torque values in the range of 10-50 N specially produced by Nucleoss company was used for
this study. After the implant application, a suitable healing cap was placed on all implants
and the wound edges were sutured with mucoperiosteal flap 3-0 silk suture so that the healing
caps would not be covered. The patients were recommended to apply a cold compress after the
surgical procedure. After the operation, Amoxicillin + Clavulanic acid 1 g (Augmentin) one
tablet twice a day for 7 days, Analgesic and anti-inflammatory Dexketoprofen 25 mg (Arveles)
one tablet twice a day for 5 days, and 0.12% chlorhexidine mouthwash (Kloroben) 3 times a day
were prescribed. The patients were informed about the points to be considered after the
procedure.
Resonance Frequency Analysis Measurement:
Penguin Resonance Frequency Analysis (RFA) (Integration Diagnostics Sweden AB) device and
MulTipeg, a transducer suitable for the implant the investigators would place, were used to
obtain the Implant Stability Quotient (ISQ) values of the implants by resonance frequency
analysis and to evaluate their stability. With the help of a MulTipeg carrier, it was
tightened and placed on the implant until resistance was encountered (manual tightening
torque of approximately 3-5 Ncm). During the use of Penguin, measurement is made without
touching the tip of the probe to the MulTipeg, therefore, it does not require any contact.
Furthermore, it is completely non-invasive and the patient does not feel anything during the
measurement, which takes a few seconds. The stability is indicated on the implant by the ISQ
value. RFA values were measured for a total of 5 times, namely immediately after implantation
and at postoperative weeks 2, 4, 6 and 12. In order to obtain the ISQ value, the arithmetic
mean of the numerical values obtained by measuring the mesio-distal and bucco-lingual total
five times in two directions perpendicular to each other was recorded as ISQ unit.
